# Heart scans after anthracyclines or chest radiotherapy for cancer in childhood, adolescence or young adulthood

Source: https://onco.cc/protocols/cardiomyopathy-surveillance-after-childhood-cancer/  
OnCo record `cardiomyopathy-surveillance-after-childhood-cancer` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some childhood cancer medicines, such as doxorubicin and daunorubicin, and radiotherapy that reached the heart can weaken the heart muscle years later, often with no symptoms at first. International guidance sorts survivors by dose: a heart ultrasound scan every 2 years after higher doses, every 5 years after middle doses, and none after low doses. Carrying on for life is thought reasonable.

## Summary

The IGHG 2022 recommendations (published 2023) replace the 2015 edition; COG Version 6.0 (October 2023) uses the same dose bands and intervals. Exposure is the cumulative anthracycline dose in doxorubicin equivalents (mitoxantrone included) and the chest radiotherapy dose. Surveillance is recommended after 250 mg/m² or more of anthracycline, 30 Gy or more of chest radiotherapy, or 100 mg/m² or more combined with 15 Gy or more (strong); it is reasonable after 100 to under 250 mg/m² or 15 to under 30 Gy (moderate); it is not recommended below 100 mg/m² or below 15 Gy (strong), which is a change from 2015. The test is left ventricular ejection fraction by 2D or 3D echocardiography, with cardiac MRI where echo windows are inadequate; blood biomarkers are not recommended as the only strategy. For high-risk survivors surveillance is recommended to start no later than 2 years after the end of cardiotoxic treatment and to repeat every 2 years (strong); for moderate-risk survivors it is reasonable to start no later than 2 years after treatment, repeat at 5 years from diagnosis and then every 5 years (moderate); lifelong surveillance is reasonable in both groups (expert opinion). An echocardiogram before pregnancy or in the first trimester is reasonable for every woman treated with anthracyclines or chest radiotherapy. Asymptomatic systolic or diastolic dysfunction is referred to cardiology, and a symptomless ejection fraction under 40 per cent is treated with heart failure medicines as in the general population.

Where the guidelines differ: COG counts radiation to the chest, abdomen, thoracic or whole spine and total body irradiation as dose with potential impact to the heart, adds a baseline ECG and a yearly history and examination, restricts pregnancy cardiology evaluation to higher exposures, and converts anthracyclines with different factors from the IGHG 2025 ratios. SIGN 132 (2013) individualises the interval up to 5 years below 250 mg/m² and 2 to 3 years above it. The ESC 2022 cardio-oncology guideline, for adults who are childhood and adolescent survivors, recommends follow-up according to IGHG and says echocardiography should be considered every 2 years (high risk) and every 5 years (moderate risk), Class IIa, Level B. This page describes guidance so that survivors and families can follow their care; the schedule set by a person's own follow-up team comes first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: cardiomyopathy surveillance in childhood cancer survivors; IGHG cardiomyopathy surveillance; echocardiogram after doxorubicin in childhood; late effects heart screening; COG echocardiogram schedule; anthracycline cardiomyopathy screening in survivors; echo every 2 years or every 5 years after childhood cancer

## Connected records

- protocols: [Breast screening after chest radiotherapy at a young age](https://onco.cc/protocols/breast-screening-after-chest-radiotherapy-at-a-young-age/), [Fall in heart pumping function (ejection fraction) on HER2-targeted drugs: scans and the hold, restart and stop rules by product](https://onco.cc/protocols/left-ventricular-dysfunction-on-her2-targeted-drugs/), [Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment](https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/), [Long-term follow-up after childhood, teenage and young adult cancer, planned by the treatment received](https://onco.cc/protocols/long-term-follow-up-after-childhood-cancer/)
- collections: [International Guideline Harmonization Group for late effects of childhood cancer](https://onco.cc/collections/ighg/)
- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [The Children's Oncology Group Long-Term Follow-Up Guidelines](https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/), [The heart after anthracyclines and chest radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-heart/)
- drugs: [Daunorubicin](https://onco.cc/drugs/daunorubicin/), [Dexrazoxane](https://onco.cc/drugs/dexrazoxane/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Idarubicin](https://onco.cc/drugs/idarubicin/), [Mitoxantrone](https://onco.cc/drugs/mitoxantrone/)
- cancers: [Adolescent and young adult cancers (ages 15 to 39)](https://onco.cc/cancers/aya-cancers/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- companies: [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/)
- terms: [Anthracyclines (doxorubicin, epirubicin)](https://onco.cc/terms/anthracycline/), [Cardiotoxicity (LVEF decline, cardiomyopathy)](https://onco.cc/terms/cardiotoxicity/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)

---
JSON: https://onco.cc/api/v1/entities/cardiomyopathy-surveillance-after-childhood-cancer.json